Affluent Prognosis of Hepatitis C after Interferon Therapy and Disease Epidemiology in Rawalpindi, Pakistan
Affluent Prognosis of Hepatitis C after Interferon Therapy and Disease Epidemiology in Rawalpindi
Keywords:
HCV, interferon, ribavirin, prognosis, treatment response, epidemiologyAbstract
Hepatitis C (HCV) affects around 3% of the world population and, thus, remains a global threat. Globally, Pakistan is at second place with regard to incidence of HCV, as 4.5-8.0% of its population is infected with HCV. Diagnosis of hepatitis C patients after interferon therapy is poorly demarcated till today. Aim of the present study was to evaluate effect of interferon, ribavirin combined therapy on survival of hepatitis C patients. This study was conducted in District Head Quarter (D.H.Q.) Teaching Hospital, Rawalpindi, Pakistan to diagnose hepatitis C after interferon combined therapy of the patients. The study span was one year and included 237 chronic hepatitis C patients. Hepatitis C diagnosis was made by polymerase chain reaction (PCR). Treatment response was evaluated by medical reports. All patients were educated for the follow-up; however, only 143 (i.e., 60%) out of the total 237 patients completed the 6-month interferon combined therapy; the remaining 94 patients (i.e., 40% of total) discontinued the treatment. The treated patients included 59 (i.e., 41%) of total 143 malesand 84(i.e., 59%) total females. Among male patients,45 (i.e., 76%)out of total 59exhibited treatment success, while 14(i.e., 24%) exhibited treatment failure. In case of female patients, 68(i.e., 81%) out of total 84 revealed treatment success and 16 (19%) revealed treatment failure. Treatment success was attributed to multiple factors, while failure occurred because of non-adherence to the treatment protocol, unawareness of the complications and/or concurrent infection with HIV.
References
World Health Organization. Hepatitis C. Weekly Epidemiological Record 72: 65-69 (1997).
Alter, M.J. Epidemiology of hepatitis C virus infection. World Journal of Gastroenterology 13:2436-2441 (2007).
Khattak, M.F., N. Salamat, F.A. Bhatti& T.Z. Qureshi. Seroprevalence of hepatitis B, C and HIV in blood donors in northern Pakistan. Journal of Pakistan Medical Association 52: 398–402 (2002).
Aziz, S., R. Khanani, W.Noorulain & J. Rajper. Frequency of hepatitis B and C in rural and periurban. Sindh Journal of Pakistan Medical Association 60: 853 (2010).
Van der Poel, C.L. Hepatitis C virus and blood transfusion: past and present risks. Journal of Hepatology 31: 101-106 (1999).
Williams & W. Lippencott. Stedman's Medical Dictionary, 26th ed. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia, Baltimore (1995).
Proceedings of the International Workshop on Epidemiology, Diagnosis and Management of Hepatitis C Infection. Medicine and the Community 67: 1-32 (1996).
Lavezzo, B. & M. Rizzetto. Treatment of recurrent hepatitis C virus infection after liver transplantation. Journal of Hepatology 31: 222-226 (1999).
World Health Organization. Hepatitis C - global prevalence (update). Weekly Epidemiological Record 74: 425-427 (1999).
EASL. International consensus conference on hepatitis C: Consensus statement. Journal of Hepatology 31: 3-8 (1999).
Pawlotsky, J.M. Diagnostic tests for hepatitis C. Journal of Hepatology 31:71-79 (1999).
Jubin, R. Amantadine and rimantadine have no direct inhibitory effects against hepatitis C viral protease, helicase, ATPase, polymerase, and internal ribosomal entry site-mediated translation. Journal of Infectious Diseases 181: 331-334 (2000).
Walker, C.M., R. Ahmed & I. Chen(Ed.).Persistent Viral Infections. Wiley,Chichester, p.93-115 (1999).
Fried, M.W. & J.H. Hoofnagl. Therapy of hepatitis C. Seminars in Liver Disease, 31 Tassopoulos NC 15: 82-91 (1995).
Wang, X. & B. Seed. Apcr primer bank for quantitative gene expression analysis. Nucleic Acids Research 154: 1-8 (2003).
Khan, J. Characterization of hepatitis c viral kinetics in vivo with clinicopathologic and therapeutic dimensions (2007).
Thomas, L. Alanine aminotransferase (ALT), Aspartate aminotransferase (AST). TH–Books Verlags Gesoll Schaft, Isted. Frankfurt 55-65 (1998).
Hauser, P. Neuropsychiatric side effects of HCV therapy and their treatment: focus on IFN alphainduced depression. Gastroenterology Clinic of North America 33: 35-50 (2004).
Wiley, T.E. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 28: 805-809 (1998).
McHutchison, J.G., S.C. Gordon & E.R. Schiff. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis. England Journal of Medicines 339: 1485-1492 (1998).
Downloads
Published
How to Cite
Issue
Section
License
Creative Commons Attribution (CC BY). Allows users to: copy the article and distribute; abstracts, create extracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation); include in a collective work (such as an anthology); and text or data mine the article. These uses are permitted even for commercial purposes, provided the user: includes a link to the license; indicates if changes were made; gives appropriate credit to the author(s) (with a link to the formal publication through the relevant DOI); and does not represent the author(s) as endorsing the adaptation of the article or modify the article in such a way as to damage the authors' honor or reputation.
